Optimal systemic therapy for premenopausal women with hormone receptor-positive breast cancer-Reference-Cited by-同舟云学术

Optimal systemic therapy for premenopausal women with hormone receptor-positive breast cancer

Published:2013-08 Issue: Volume:22 Page:S165-S170
ISSN:0960-9776
Container-title:The Breast
language:en
Short-container-title:The Breast

Author:

Jankowitz Rachel C.,McGuire Kandace P.,Davidson Nancy E.

Publisher

Elsevier BV

Subject

General Medicine,Surgery

Reference38 articles.

1. http://www.cancer.org/cancer/breastcancer/detailedguide/breast-cancer-key-statistics [accessed Jan 2013].

2. Breast cancer facts and figures 2011–2012. http://www.cancer.org/research/cancerfactsfigures/breastcancerfactsfigures/breast-cancer-facts-and-figures-2011-2012 [accessed Jan 2013].

3. Improvement in breast cancer outcomes over time: are older women missing out?;Smith;J ClinOncol,2011

4. Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel project B-14 randomized trial;Fisher;J Natl Cancer Inst,2001

5. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors;Fisher;J Natl Cancer Inst,1996

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Toward a Value-Based Therapy Recommendation Model;Healthcare;2023-08-21

2. Inclusion of premenopausal women in breast cancer clinical trials;The Breast;2022-12

3. Mammakarzinom: Update 2019;Deutsches Ärzteblatt Online;2019-11-15

4. Breast cancer in young patients. Peculiarities of prognosis and adjuvant hormone therapy (a literature review);Tumors of female reproductive system;2018-10-16

5. Luteininzing hormone releasing hormones analogs in combination with tamoxifen for the adjuvant treatment of premenopausal women with hormone receptor positive breast cancer;Expert Opinion on Pharmacotherapy;2017-08-10